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Background. Malignant melanoma incidence is increasing dramatically. We report herein a case of the rarest acral lentiginous type.
Case Report. A 58-year-old man presented with a melanoma resembling lesion over the sole of his right foot, measuring 15–20mm
in diameter. An excisional biopsy with a narrow (2mm) margin of surrounding skin was obtained. Histological ﬁndings were
consistent with a diagnosis of acral lentiginous melanoma. Sentinel lymph node biopsy was also performed and micrometastases
were not identiﬁed in frozen-section examination. According to the AJCC system, the tumor stage was IB (T2aN0M0). A wide
local excision of the biopsy scar with a margin of 2cm was performed. A split-thickness thick skin graft was used to reconstruct
the excisional defect. During an 18-month followup, no local or distant recurrence has been observed. This paper aims to extract
an updated rational approach to the management of this disease out of an enormous body of knowledge.
1.Introduction
Theincidenceofmalignantmelanomaisrisingataratefaster
than any other form of cancer [1]. However, the mortality
rate has fallen over the years, probably as the result of
increased public awareness and education programs leading
to earlier detection and treatment [2]. There are four distinct
categories of melanoma. These are, in order of decreasing
frequency, superﬁcial spreading, nodular, lentigo maligna,
and acral lentiginous. We report herein a case of the rarer
acral lentiginous type and aim to extract a rational approach
to the management of this disease out of an enormous body
of knowledge.
2. Case Presentation
A 58-year-old man presented with a 12-month history of
a ﬂat lesion that spread over the sole of his right foot and
later became elevated, measuring 15–20mm in diameter
(Figure 1). Clinically, the lesion resembled acral lentiginous
melanoma (ALM). Cutaneous examination was otherwise
normal; no dysplastic or congenital nevi were identiﬁed.
He was in otherwise good health, with no predisposing
factors (family or personal history of melanoma, blond or
red hair, freckling of the upper back, blistering sunburn
beforeage20,actinickeratosis,andblue,green,orgrayeyes).
There was no evidence of clinically apparent lymph node
(inguinal) metastasis. The patient underwent an excisional
biopsy of the suspicious lesion, including a layer of the
underlying fatty tissue and the entire visible tumor, under
local anesthesia. A narrow (2mm) margin of surrounding
skin was obtained and the wound was closed primarily
in two layers in an orientation that was consistent with
a possible subsequent wider excision. Histological ﬁndings
were consistent with a diagnosis of ALM: intradermal
features showing a diﬀuse proliferation of large atypical
melanocytesalongtheepidermal-dermaljunctionwhichwas
dispersed in a lentiginous pattern with marked acanthosis2 Case Reports in Medicine
Figure 1: The lesion over the sole of patient’s right foot, measuring
15–20mm in diameter.
Figure 2: Perform of a wide local excision of the skin and
underlying subcutaneous tissues with a margin of 2cm.
and elongation of the rete ridges. The complete pathologic
report included the following: Breslow thickness: 1,6mm,
absence of ulceration, Clark level II, negative surgical
margins, absence of satellitosis, and absence of regression.
Following the diagnosis, the patient was subjected to a
thorough diagnostic evaluation to determine the possible
spread of the disease to other sites. History focused on
constitutional, central nervous system, pulmonary, gastroin-
testinal, and soft tissue symptoms; physical examination
included a detailed inspection and palpation of the skin and
subcutaneous tissue to detect satellites, in-transit metastases,
other primary tumors, and lymph node enlargement; chest
X-ray and abdominal ultrasonography were all negative
for the presence of disease. Sentinel lymph node biopsy
was consequently performed. The ﬁrst (sentinel) lymph
node draining the tumor was identiﬁed, removed, and
since micrometastases were not identiﬁed in frozen-section
examination, a complete lymph node dissection was not
performed. According to the American Joint Committee on
Cancer (AJCC) system of TNM (tumor, node, metastasis)
classiﬁcation, the tumor stage was IB (T2aN0M0). A wide
local excision of the skin and underlying subcutaneous
t i s s u e sw a sp e r f o r m e dw i t ham a r g i no f2 c m( Figure 2).
A split-thickness thick (>0.016 inches) skin graft was used
to reconstruct the excisional defect, providing an excellent
aesthetic result (Figures 3(a) and 3(b)). The donor site was
the anterior surface of the right thigh, which was left to heal
by secondary intention. During an 18-month followup, no
local or distant recurrence was observed.
3. Discussion
The term ALM was ﬁrst described by Reed as a subtype of
melanoma [3]. It was so named owing to its predilection of
acral areas of the body, in particular the palms, soles, and
the subungual areas, and its distinct radial or “lentiginous”
growth phase. Although ALM is the rarest subtype of cuta-
neous melanoma, it represents the most common category
diagnosed on the foot [4].
Clinical management of melanoma begins with an
accurate diagnosis. Clinicians should have a low threshold to
perform a diagnostic biopsy on any changing lesion. In our
case the decision to perform a biopsy of the suspicious lesion
was based on clinical experience.
A 1–3mm margin of normal skin is taken if the wound
can be closed primarily. Wider margins should be avoided to
permit accurate subsequent lymphatic mapping. If removal
of the entire lesion creates too large a defect, then punch
biopsy or excision of a representative segment of the lesion
isrecommended.Onceadiagnosis ofmelanomaismade,the
biopsy scar and any remains of the lesion need to be removed
to eradicate any remaining tumor. The size of the surgical
marginsdependsonthetumorthickness.Forinsitulesionsa
0.5-to1-cmmarginofnormalskinisadequateforcure.Thin
melanomas (≤1mm) require a 1-cm margin to prevent local
recurrence; lesions between 1,01 and 2mm should have a
marginof1-2cm.Forlesionsbetween2,01and4mm,a2cm
margin is recommended. Extending the resection beyond
2cm does not appear to decrease local recurrence rates.
Melanoma of ﬁngers and toes requires digital amputation
[5, 6].
The surrounding tissue should be removed down to
the superﬁcial fascia to remove all lymphatic channels. If
the deep fascia is not involved by the tumor, removing
it does not aﬀect recurrence or survival rates, so the
fascia is left intact. Generally, the wounds should be closed
primarily. Larger tissue defects may be closed with local
rotational/advancement skin ﬂaps or a skin graft [7].
Evidence of tumor in regional lymph nodes is a poor
prognostic sign. This is accounted for in the staging system
by advancing any T classiﬁcation from Stage I or II to
Stage III. All clinically positive lymph nodes should be
removed by regional nodal dissection unless unresectableCase Reports in Medicine 3
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Figure 3:Useofasplit-thicknessthick(>0.016inches)skingraftfromanteriorsurfaceoftherightthighinordertoreconstructtheexcisional
defect and provide an excellent aesthetic result.
distant metastases are present. Therapeutic lymph node
dissection includes a superﬁcial inguinal lymphadenectomy.
The deep (iliac and obturator) nodes should be removed
in the presence of clinical or radiographic evidence of deep
node involvement or if there are more than three positive
superﬁcial nodes or when Cloquet’s node is positive [8–11].
For patients with lesions less than 0.75mm the tumor
cells are still localized in the surrounding tissue, and
treatment of regional lymph nodes is not beneﬁcial. With
lesions more than 4mm, it is highly likely that the tumor
cells have already spread to the regional lymph nodes and
distant sites. Removal of the lymph nodes has no eﬀect on
survival [12, 13]. In patients with intermediate-thickness
tumors (0.76 to 4.0mm) and no clinical evidence of nodal or
metastatic disease the eﬃcacy of sentinel lymph node (SLN)
biopsy has been established [13–18]. By using a combination
of isotope lymphatic mapping, an intraoperative hand-
held gamma probe, and intraoperative injection of blue
dye, the SLN can be identiﬁed in more than 95% of
cases in the groin and axilla. The sentinel node(s) is (are)
removed, and if micrometastases are identiﬁed in frozen-
section examination, a complete lymph node dissection
is performed. Recently, detailed pathologic analysis of the
sentinel nodes via step sections and immunohistochemistry
along with diagnosis of submicroscopic disease based on
genetic changes detectable by the polymerase chain reaction,
enabled detection of micrometastases that could be missed
by standard techniques [19].
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